Major step forward in effective treatment for HIV/AIDSAugust 30, 2002FROM PROCEEDINGS B OF THE ROYAL SOCIETY ONLINE ACCESS VIA FIRSTCITE FROM: 4 September 2002 New research findings by scientists in Germany* - soon to be published in The Royal Society`s Proceedings B journal - will be of major importance for HIV and AIDS treatment in the future. The findings provide estimates on the likely success of drugs which are currently in development and clarifies key factors of HIV dynamics that must be eliminated to pave the way for an efficient treatment of HIV/AIDS. Using computer simulations to map the `predator-prey` dynamics between viruses and the immune system, the research offers a better understanding of the conditions that inhibit the progression of the virus into AIDS and the points at which HIV may be most effectively defeated. Commenting on the research, Christel Kamp, from the Institute of Theoretical Physics, University of Kiel, says: "Our research findings are a step ahead in understanding conditions that promote a non-progression to AIDS, suggesting vaccination and receptor blocking/fusion inhibition as efficient ways of overcoming an HIV infection. Receptor blocking is a process by which the HIV strains are blocked from attaching to markers on the T-helper cells which are necessary to start the process of cell membrane fusion. The first clinical trials are also showing these strategies to be very promising." Deriving explanations for the origin of the unusual incubation period in the development of AIDS is closely connected to the identification of vaccination and receptor blocking as effective strategies to overcome HIV infection. Vaccination leads to an adaptation of the immune repertoire to HIV, which allows a faster response to the virus. In the research model used by the German scientists, this leads to a stabilisation of the system and an enhanced probability that the virus dies out. T-helper cells are crucial in the immune system response. They detect antigens on the surface of cells and stimulate other immune cells that produce antibodies. HIV strains enter the T-helper cells, then use the replication machinery of these cells with the result that the new virus particles spill out of the cell which is finally destroyed. Therefore, patients that do not express these receptors have shown a resistance to HIV. | |||||||||||||||||||||
|
Related AIDS Current Events and AIDS News Articles Study sheds light on causes of HIV dementia A new study led by researchers at Albert Einstein College of Medicine of Yeshiva University has clarified how two major variants of HIV differ in their ability to cause neurologic complications. New HIV film tackles stigma faced by teachers in Africa Addressing the discrimination against HIV-positive teachers in Africa is a key aim of a new documentary and accompanying book being launched in Senegal today by the Partnership for Child Development based at Imperial College London. Selenium may slow march of AIDS Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists. Claudin 11 stops the leaks in neuronal myelin sheaths Devaux and Gow demonstrate how a tight junction protein called claudin 11 makes the neuronal myelin sheath a snug fit. ACP recommends routine HIV screening for all patients On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org. Scientists build 'roach motel' for nasty bugs of the bacterial variety The vacancy sign is on, but the lowlifes who check in never check out. Scientists at the University of Florida and the University of New Mexico have created tiny microscopic spheres that trap and kill harmful bacteria in a manner the scientists liken to "roach motels" snaring and killing cockroaches. Study of ancient and modern plagues finds common features In 430 B.C., a new and deadly disease-its cause remains a mystery-swept into Athens. The walled Greek city-state was teeming with citizens, soldiers and refugees of the war then raging between Athens and Sparta. Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. Landmark study defines benefits of early HIV testing and treatment for infected infants Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine. More AIDS Current Events and AIDS News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||